Measurement of response rate and time to disease progression in patients with chronic lymphocytic leukemia using fludarabine and the anti-CD20 antibody rituximab (IDEC-C2B8).
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 09 Jun 2006 New trial record.